Cargando…

Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer

Bromo and extraterminal domain (BET) inhibitors-PROteolysis TArgeting Chimera (BETi-PROTAC) is a new family of compounds that induce proteasomal degradation through the ubiquitination of the tagged to BET inhibitors Bromodomain proteins, BRD2 and BRD. The encapsulation and controlled release of BET-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cimas, Francisco J., Niza, Enrique, Juan, Alberto, Noblejas-López, María del Mar, Bravo, Iván, Lara-Sanchez, Agustín, Alonso-Moreno, Carlos, Ocaña, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589709/ https://www.ncbi.nlm.nih.gov/pubmed/33086530 http://dx.doi.org/10.3390/pharmaceutics12100986

Ejemplares similares

An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy
por: Juan, Alberto, et al.
Publicado: (2020)

Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles
por: Juan, Alberto, et al.
Publicado: (2022)

Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2019)

Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers
por: Juan, Alberto, et al.
Publicado: (2022)

Polyester Polymeric Nanoparticles as Platforms in the Development of Novel Nanomedicines for Cancer Treatment
por: Niza, Enrique, et al.
Publicado: (2021)

Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment
por: Juan, Alberto, et al.
Publicado: (2020)

MZ1 co-operates with trastuzumab in HER2 positive breast cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2021)

Clinical considerations for the design of PROTACs in cancer
por: Nieto-Jiménez, Cristina, et al.
Publicado: (2022)

Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast Cancer
por: Niza, Enrique, et al.
Publicado: (2019)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
por: Ocaña, Alberto, et al.
Publicado: (2020)

Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2022)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
por: Negi, Arvind, et al.
Publicado: (2022)

Poly(Cyclohexene Phthalate) Nanoparticles for Controlled Dasatinib Delivery in Breast Cancer Therapy
por: Niza, Enrique, et al.
Publicado: (2019)

The BET PROTAC inhibitor dBET6 protects against retinal degeneration and inhibits the cGAS-STING in response to light damage
por: Zhu, Xingfei, et al.
Publicado: (2023)

Targeting BET Proteins With a PROTAC Molecule Elicits Potent Anticancer Activity in HCC Cells
por: Zhang, Huapeng, et al.
Publicado: (2020)

PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis
por: Shi, Chengcheng, et al.
Publicado: (2019)

Tuning the Cytotoxicity of Bis-Phosphino-Amines Ruthenium(II) Para-Cymene Complexes for Clinical Development in Breast Cancer
por: Domínguez-Jurado, Elena, et al.
Publicado: (2021)

Transcriptomic Profiles of CD47 in Breast Tumors Predict Outcome and Are Associated with Immune Activation
por: Noblejas-López, María del Mar, et al.
Publicado: (2021)

BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes
por: Ma, Li, et al.
Publicado: (2022)

BET inhibitors as novel therapeutic agents in breast cancer
por: Ocaña, Alberto, et al.
Publicado: (2017)

Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs
por: Muddassir, Mohd., et al.
Publicado: (2020)

PROTAC-DB: an online database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2020)

$m_b$ at $M_Z$
por: Abreu, P, et al.
Publicado: (1997)

m_b at M_Z
por: DELPHI Collaboration
Publicado: (2018)

Determination of $\alpha _s(m_Z)$ by the non-perturbative decoupling method
por: Dalla Brida, Mattia, et al.
Publicado: (2022)

PROTAC-DB 2.0: an updated database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2022)

On the relevance of the dependence of the t, s-t correction on M_Z
por: Quast, G, et al.
Publicado: (1999)

Natural history of MZ B cells
por: Nemazee, David
Publicado: (2021)

PROTACs: Walking through hematological malignancies
por: Bou Malhab, Lara J., et al.
Publicado: (2023)

Do MZ twins have discordant experiences of friendship? A qualitative hypothesis-generating MZ twin differences study
por: Asbury, Kathryn, et al.
Publicado: (2017)

Novel BET protein Proteolysis Targeting Chimera (BET-PROTAC) exerts superior lethal activity than Bromodomain Inhibitor (BETi) against post-myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells
por: Saenz, Dyana T., et al.
Publicado: (2017)

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
por: Ma, Sinan, et al.
Publicado: (2022)

Correction: Do MZ twins have discordant experiences of friendship? A qualitative hypothesis-generating MZ twin differences study
por: Asbury, Kathryn, et al.
Publicado: (2017)

PROTACs in gastrointestinal cancers
por: Chen, Yu, et al.
Publicado: (2022)

DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
por: Li, Fenglei, et al.
Publicado: (2022)

Draft Genome Sequences of Two Streptomyces Strains, MZ03-37(T) and MZ03-48, Isolated from Lava Tube Speleothems
por: Gonzalez-Pimentel, Jose L., et al.
Publicado: (2020)

Precision NNLO determination of alpha_s(M_Z) using an unbiased global parton set
por: Ball, Richard D., et al.
Publicado: (2011)

Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4
por: Maneiro, María, et al.
Publicado: (2020)

Mithramycin delivery systems to develop effective therapies in sarcomas
por: Estupiñán, Óscar, et al.
Publicado: (2021)

Screening and Preliminary Biochemical and Biological Studies of [RuCl(p-cymene)(N,N-bis(diphenylphosphino)-isopropylamine)][BF(4)] in Breast Cancer Models
por: Corrales Sánchez, Veronica, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gqpp3gea7qej0kfqeuskobbkqq